1-3 of 3
Marie Green
Close
Sort by
Journal Articles

Front-Line, Dose-Escalated Immunochemotherapy Is Associated with a Significant PFS (but not OS) Advantage in 401 Patients (Pts) with Double-Hit Lymphomas (DHL): A Systematic Review and Meta-Analysis

Christina Howlett, PharmD, BCOP, Daniel J. Landsburg, MD, Elise A. Chong, MD, Sonya J Snedecor, PhD, Stephen J. Schuster, MD, Tina Marie Green, MD, Jonathon B. Cohen, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Tatyana Feldman, MD, Allison Rago, BSN, Danielle Land, CRNP, Kristy M. Walsh, BS, Andre Goy, MD, Anthony R. Mato, MD MSCE
Journal: Blood
Blood (2014) 124 (21): 3056.
https://doi.org/10.1182/blood.V124.21.3056.3056
Published: 2014
Journal Articles

Development of BET Protein Bromodomain Inhibition for the Treatment of Hematologic Malignancies

Robert Sims, PhD, Emmanuel Normant, PharmD, PhD, Peter Sandy, PhD, Jennifer Mertz, PhD, Barbara Bryant, PhD, Michael O'Meara, MS, Marie Green, PhD, Michael Cooper, MD, Jim Audia, PhD
Journal: Blood
Blood (2012) 120 (21): 1331.
https://doi.org/10.1182/blood.V120.21.1331.1331
Published: 2012
Journal Articles

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

Clinical Trials & Observations
Robert Z. Orlowski, Peter M. Voorhees, Reynaldo A. Garcia, Melissa D. Hall, Fred J. Kudrik, Tammy Allred, Anandhi R. Johri, Paul E. Jones, Anastasia Ivanova, Hendrik W. Van Deventer, Don A. Gabriel, Thomas C. Shea, Beverly S. Mitchell, Julian Adams, Dixie-Lee Esseltine, Elizabeth G. Trehu, Marie Green, Mary Jo Lehman, Susan Natoli, Jason M. Collins, Celeste M. Lindley, E. Claire Dees
Journal: Blood
Blood (2005) 105 (8): 3058–3065.
https://doi.org/10.1182/blood-2004-07-2911
Published: 2005